This platform gives access to an expanded complementary determining region (CDR) diversity that allows for rapid discovery of antibodies against (i) therapeutically relevant epitopes, (ii ...

Paratope-PLUS™ involves mutating each residue of an antibody's CDRs (Complementarity Determining Regions) to all 19 other amino acids, identifying every variant that retains or enhances function.

CDR-Life develops highly targeted T cell engagers ... demonstrates the potential of our antibody-derived molecules. Backed by leading cross-Atlantic investors, our team is committed to bringing ...

Sino Biological delivers high-quality monoclonal antibody humanization services with a high degree of success (>90%) utilizing complementarity-determining region (CDR) grafting technology and ...

Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

BI 771716, engineered using CDR-Life's proprietary technology and developed by Boehringer Ingelheim, represents a potential breakthrough in retinal therapy. Its unique antibody fragment design ...

Portfolio Expansion: CDR111 CDR111, CDR-Life's newest clinical candidate ... AACR Poster Presentation Details Title: A novel T cell engager antibody for the treatment of HLA-A*01/KK-LC-1-positive ...

The first anti-amyloid monoclonal antibody -- and the first drug of any ... on the 18-point Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale over 18 weeks. Mean baseline score was about ...